These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 738344)

  • 21. [CEA--a parameter in the course of chemotherapy of ovarian cancer].
    Urdl W; Pickel H; Pürstner P; Schrödl P
    Gynakol Rundsch; 1980 Jun; 20 Suppl 2():90-7. PubMed ID: 7194302
    [No Abstract]   [Full Text] [Related]  

  • 22. Ovarian cancer chemotherapy: carboplatin as standard.
    Tattersall MN
    Lancet; 2002 Aug; 360(9332):500-1. PubMed ID: 12241648
    [No Abstract]   [Full Text] [Related]  

  • 23. [Palliative and second-look operations in ovarian cancer].
    Grünberger V; Dobrovits H; Hoffelner L
    Gynakol Rundsch; 1980 Jun; 20 Suppl 2():131-4. PubMed ID: 6163684
    [No Abstract]   [Full Text] [Related]  

  • 24. Second trial drugs in ovarian cancer.
    Stanhope CR; Smith JP; Rutledge F
    Gynecol Oncol; 1977 Mar; 5(1):52-8. PubMed ID: 404216
    [No Abstract]   [Full Text] [Related]  

  • 25. Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia.
    Presant CA; Klahr C; Santala R
    Ann Intern Med; 1977 Jan; 86(1):47-51. PubMed ID: 264783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adriamycin versus adriamycin plus melphalan in advanced ovarian carcinoma.
    De Palo GM; De Lena M; Bonadonna G
    Cancer Treat Rep; 1977; 61(3):355-7. PubMed ID: 326402
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP).
    Bruckner HW; Cohen CJ; Deppe G; Kabakow B; Wallach R; Ratner L; Holland JF
    Gynecol Oncol; 1981 Oct; 12(2 Pt 1):150-3. PubMed ID: 6795095
    [No Abstract]   [Full Text] [Related]  

  • 28. Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide.
    Mazzei T; Bonazza M; Amunni G; Scarselli G; Branconi F; Massi GB
    Chemioterapia; 1984 Feb; 3(1):10-5. PubMed ID: 6535650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.
    Bruckner HW; Pagano M; Falkson G; Creech R; Arseneau JC; Horton J; Brodovsky H; Davis TE; Slayton RW; Greenspan E
    Cancer Treat Rep; 1979 Feb; 63(2):297-9. PubMed ID: 376136
    [No Abstract]   [Full Text] [Related]  

  • 30. High-dose intensity regimens with epirubicin in ovarian cancer.
    Vermorken JB
    Pathol Biol (Paris); 1992 Nov; 39(9):833. PubMed ID: 1538894
    [No Abstract]   [Full Text] [Related]  

  • 31. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. K cell activity in ovarian cancer patients given chemotherapy.
    Mantovani A; Polentarutti N; Gritti P; Bolis G; Maggioni A; Spreafico F
    Eur J Cancer (1965); 1979 May; 15(5):797-802. PubMed ID: 510340
    [No Abstract]   [Full Text] [Related]  

  • 33. Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in the treatment of advanced ovarian cancer: a randomized study.
    Krommer CF; Szalai JP
    Ann Oncol; 1992 Jan; 3(1):37-9. PubMed ID: 1606067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma.
    Wharton JT; Herson J; Edwards CL; Griffith AB
    Gynecol Oncol; 1982 Oct; 14(2):262-70. PubMed ID: 6813202
    [No Abstract]   [Full Text] [Related]  

  • 35. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study).
    Sutton GP; Bundy BN; Omura GA; Yordan EL; Beecham JB; Bonfiglio T
    Gynecol Oncol; 1991 Jun; 41(3):230-3. PubMed ID: 1869100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapy.
    Sessa C; Bolis G; Valente I; Mangioni C; D'Incalci M
    Cancer Treat Rep; 1981; 65(1-2):172-3. PubMed ID: 6784922
    [No Abstract]   [Full Text] [Related]  

  • 37. [Epithelial ovarian cancer: a challenge in gynecologic oncology].
    Dauplat J; Piccart M
    Pathol Biol (Paris); 1992 Nov; 39(9):823-4. PubMed ID: 1538891
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of transplanted adriamycin-resistant ovarian cancers in mice by combination of adriamycin and ultrasound exposure.
    Yu T; Huang X; Hu K; Bai J; Wang Z
    Ultrason Sonochem; 2004 Jul; 11(5):287-91. PubMed ID: 15157857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A randomized clinical trial of cyclophosphamide versus adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate in advanced ovarian carcinoma--a preliminary report ].
    Chylak V; Ilijas M; Krusić J; Kolarić K
    Lijec Vjesn; 1982; 104(3-4):120-2. PubMed ID: 6750298
    [No Abstract]   [Full Text] [Related]  

  • 40. [Preliminary report on the treatment of ovarian cancer with adriamycin following full conventional treatment (author's transl)].
    Wolf A; Vahrson H
    Geburtshilfe Frauenheilkd; 1977 Mar; 37(3):224-7. PubMed ID: 858485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.